In this study, we analyzed the profile of leukemic blast-derived EVs (EV-CD34+/CD10+/CD19+) in the peripheral blood (PB) and BM plasma of pediatric patients with B-ALL (B-ALL PB and B-ALL BM, respectively), at diagnosis baseline (D0) and during induction therapy (D15 and D35). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.